Venous Vascular Pharmacology: A New Frontier in HFpEF Management?

Heart failure with preserved ejection fraction (HFpEF) causes significant cardiovascular morbidity globally. Therefore, experts are investigating how venous vascular pharmacology influences disease progression. Specifically, the venous system functions as the body’s primary capacitance system. Because it determines central venous pressure, any dysfunction impacts heart health. Traditionally, research focused on arterial pathways. However, emerging evidence shows that venous endothelial dysfunction is a key driver of the disease. Specifically, an imbalance between relaxing and contractile factors increases venous tone. Consequently, this elevation leads to higher mean circulatory filling pressure and ventricular-vascular mismatch.

Advancements in Venous Vascular Pharmacology

Current reviews synthesize the vasoactive effects of endothelial-derived relaxing factors (EDRF) and contractile factors (EDCF). These mediators behave differently in the venous system compared to the arterial system. For example, increased venous tone reduces the capacity of the veins to store blood. Moreover, this shift forces blood into the central circulation, which worsens heart failure symptoms. Scientists have studied these effects in healthy and hypertensive animal models. However, we currently lack sufficient data from validated HFpEF models. Therefore, future research must bridge this gap to identify better therapeutic targets.

Clinical Implications and Future Research

Clinical studies should prioritize functional assessments of the venous system. Specifically, researchers suggest using direct measures of venous compliance as endpoints. Additionally, understanding how current HFpEF therapies like SGLT2 inhibitors or mineralocorticoid receptor antagonists affect the veins is vital. Because the venous system contains most of the blood volume, even small changes in its tone can significantly improve cardiac output. Thus, targeting the venous endothelium might offer a novel pathway for managing resistant symptoms. Consequently, a deeper focus on venous health could transform the standard of care for HFpEF patients.

Frequently Asked Questions

What is the role of the venous system in HFpEF?

The venous system acts as a capacitance reservoir. In HFpEF, increased venous tone and reduced compliance shift blood volume centrally, leading to elevated filling pressures.

How does endothelial dysfunction affect veins?

Endothelial dysfunction creates an imbalance between relaxing and contractile factors. This causes the veins to stiffen, which increases mean circulatory filling pressure and exacerbates heart failure.

Why is venous vascular pharmacology important for future treatments?

Most current heart failure drugs target the arterial system or kidneys. Focusing on venous vascular pharmacology allows doctors to address the primary reservoir of blood volume directly.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or establish a doctor-patient relationship. Always seek the advice of a qualified healthcare provider for medical concerns. Refer to the latest local and national guidelines for clinical practice.

References

Lineham J et al. Venous vascular pharmacology: how does it contribute to heart failure with preserved ejection fraction? Eur Heart J Cardiovasc Pharmacother. 2026 May 29. doi: undefined. PMID: 42213452.

Fudim M et al. Venous Tone and Stressed Blood Volume in Heart Failure: JACC Review Topic of the Week. J Am Coll Cardiol. 2022;79(18):1858-1869.

Savarese G et al. Advances in the Pharmacological Treatment of Heart Failure With Preserved Ejection Fraction. Korean Soc Heart Fail. 2026 Jan; PMC12901533.